|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 7 (April 1), 2000:
pp. 2253-2261
Significance of cyclin D1 overexpression for the diagnosis of
mantle cell lymphoma: a clinicopathologic comparison of cyclin
D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma
Yasushi Yatabe,
Ritsuro Suzuki,
Kensei Tobinai,
Yoshihiro Matsuno,
Ryo Ichinohasama,
Masataka Okamoto,
Motoko Yamaguchi,
Jun-ichi Tamaru,
Naokuni Uike,
Yuko Hashimoto,
Yasuo Morishima,
Taizan Suchi,
Masao Seto, and
Shigeo Nakamura
From the Department of Pathology and Clinical
Laboratories, Laboratory of Chemotherapy, and
the Department of Hematology and Chemotherapy, Aichi Cancer
Center, Nagoya; the Departments of Medical Oncology
and Pathology, National Cancer Center, Tokyo;
the Department of Pathology, Tohoku University School of Medicine,
Sendai; the Department of Internal Medicine, Fujita Health
University School of Medicine, Nagoya; the Second
Department of Internal Medicine, Mie University School of Medicine,
Tsu; the First Department of Pathology, Chiba University
School of Medicine, Chiba; the Department of
Hematology, National Kyushu Cancer Center, Fukuoka; and the
First Department of Pathology, Fukushima Medical College,
Fukushima, Japan.
Mantle cell lymphoma (MCL) is a distinct clinicopathologic entity of
non-Hodgkin's lymphoma, characterized by a monotonous proliferation of
small to medium-sized lymphocytes with co-expression of CD5 and CD20,
an aggressive and incurable clinical course, and frequent
t(11;14)(q13;q32) translocation. We examined 151 cases of lymphoma with
MCL morphology from a viewpoint of cyclin D1 overexpression, which is
now easily detectable by immunohistochemistry. 128 cases (85%) showed
positive nuclear staining for cyclin D1, while the remaining 23 (15%)
were negative. Except for cyclin D1 immunohistochemistry, current
diagnostic methods, including morphological and phenotypical
examinations, could not make this distinction. Although both the cyclin
D1-positive and -negative groups were characterized by male
predominance, advanced stages of the disease, frequent extranodal
involvement, and low CD23 reactivity, the cyclin D1-positive group
showed a higher age distribution (P = .04), larger cell
size (P = .02), higher mitotic index (P = .01),
more frequent gastrointestinal involvement (P = .05), higher international prognostic index score (P = .05), and
lower p27KIP1 expression (P < .0001). Of
particular interest is that cyclin D1-positive MCL showed significantly
worse survival than cyclin D1-negative lymphoma (5-year survival: 30%
versus 86%, P = .0002), which was confirmed by
multivariate analysis to be independent of other risk factors. These
data suggest that cyclin D1-positive and -negative groups may represent
different entities and that the former closely fits the characteristics
of classical, typical MCL. We therefore propose that cyclin
D1-positivity should be included as one of the standard criteria for
MCL, and that innovative therapies for this incurable disease should be
explored on the basis of the new criteria. (Blood.
2000;95:2253-2261
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
I. Wlodarska, D. Dierickx, V. Vanhentenrijk, K. Van Roosbroeck, H. Pospisilova, F. Minnei, G. Verhoef, J. Thomas, P. Vandenberghe, and C. De Wolf-Peeters
Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas
Blood,
June 15, 2008;
111(12):
5683 - 5690.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Ortega-Paino, J. Fransson, S. Ek, and C. A. K. Borrebaeck
Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference
Blood,
February 1, 2008;
111(3):
1617 - 1624.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Watanabe, N. Homma, N. Ogata, H. Saito, T. Kanefuji, K. Hasegawa, K. Soga, K. Shibasaki, T. Endo, and Y. Ajioka
Complete response in a patient with colonic mantle cell lymphoma with multiple lymphomatous polyposis treated with combination chemotherapy using anti-CD20 antibody and cladribine
Gut,
March 1, 2007;
56(3):
449 - 450.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Morton, S. S. Wang, S. S. Devesa, P. Hartge, D. D. Weisenburger, and M. S. Linet
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001
Blood,
January 1, 2006;
107(1):
265 - 276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Fu, D. D. Weisenburger, T. C. Greiner, S. Dave, G. Wright, A. Rosenwald, M. Chiorazzi, J. Iqbal, S. Gesk, R. Siebert, et al.
Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling
Blood,
December 15, 2005;
106(13):
4315 - 4321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jones, K. H. Darnell, R. A. Warnke, and J. L. Zehnder
CyclinD1/CyclinD3 Ratio by Real-Time PCR Improves Specificity for the Diagnosis of Mantle Cell Lymphoma
J. Mol. Diagn.,
May 1, 2004;
6(2):
84 - 89.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Thieblemont, V. Nasser, P. Felman, K. Leroy, S. Gazzo, E. Callet-Bauchu, B. Loriod, S. Granjeaud, P. Gaulard, C. Haioun, et al.
Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis
Blood,
April 1, 2004;
103(7):
2727 - 2737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Walsh, M. Thorselius, A. Johnson, O. Soderberg, M. Jerkeman, E. Bjorck, I. Eriksson, U. Thunberg, O. Landgren, M. Ehinger, et al.
Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma
Blood,
May 15, 2003;
101(10):
4047 - 4054.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Igarashi, Y. Kobayashi, M. Ogura, T. Kinoshita, T. Ohtsu, Y. Sasaki, Y. Morishima, T. Murate, M. Kasai, N. Uike, et al.
Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study
Ann. Onc.,
June 1, 2002;
13(6):
928 - 943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Yamaguchi, M. Seto, M. Okamoto, R. Ichinohasama, N. Nakamura, T. Yoshino, J. Suzumiya, T. Murase, I. Miura, T. Akasaka, et al.
De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients
Blood,
February 1, 2002;
99(3):
815 - 821.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Falini and D. Y. Mason
Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry
Blood,
January 15, 2002;
99(2):
409 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Suzuki, K. Takemura, M. Tsutsumi, S. Nakamura, N. Hamajima, and M. Seto
Detection of Cyclin D1 Overexpression by Real-Time Reverse-Transcriptase-Mediated Quantitative Polymerase Chain Reaction for the Diagnosis of Mantle Cell Lymphoma
Am. J. Pathol.,
August 1, 2001;
159(2):
425 - 429.
[Abstract]
[Full Text]
|
|
|
|
|
